Revvity Reports 4% Revenue Growth to $720.3 Million in Q2 2025

Revvity, Inc. reported its financial results for the second quarter of fiscal year 2025, revealing a total revenue of $720.3 million, a 4% increase from $691.7 million in the same period last year. The growth was driven by a 5% increase in the Life Sciences segment, which generated $365.9 million, and a 3% increase in the Diagnostics segment, which brought in $354.4 million. The company’s net income for the quarter was $53.9 million, slightly down from $55.4 million in the prior year, resulting in diluted earnings per share of $0.46 compared to $0.45.

In comparison to the previous fiscal period, Revvity's revenue for the first six months of 2025 reached $1.385 billion, up from $1.342 billion in the same timeframe last year, marking a 3% increase. The company’s operating income from continuing operations also saw an increase, rising to $163 million for the six months ended June 29, 2025, compared to $129.8 million in the prior year. However, the overall gross margin decreased by 123 basis points to 54.5% due to increased tariffs and shifts in product mix, despite pricing actions that partially offset these challenges.

Strategically, Revvity has undergone significant organizational changes, including the integration of its Applied Genomics business into a newly formed Life Sciences Solutions segment. This restructuring aims to enhance operational efficiency and align product offerings more closely with market demands. The company also continued its stock repurchase program, having repurchased approximately 4.4 million shares for $443 million in the first half of 2025, with $414.5 million remaining under the authorized $1 billion repurchase program.

Operationally, Revvity reported a decrease in cash and cash equivalents to $991.8 million as of June 29, 2025, down from $1.163 billion at the end of the previous fiscal year. The company’s employee headcount remained stable, and it continues to focus on expanding its market presence, particularly in the Life Sciences and Diagnostics sectors. The company’s international sales accounted for a significant portion of its revenue, highlighting its global reach and the importance of foreign markets to its overall strategy.

Looking ahead, Revvity anticipates continued revenue growth driven by its strategic initiatives and product innovations. The company expects to navigate challenges related to tariffs and market conditions through a comprehensive mitigation strategy, which includes optimizing manufacturing processes and adjusting pricing. Management remains optimistic about the company’s ability to sustain profitability and enhance shareholder value through disciplined financial management and targeted investments in growth opportunities.